<DOC>
	<DOCNO>NCT02049346</DOCNO>
	<brief_summary>* Background : Despite extensive use , best knowledge , trial simultaneously compare three currently use erythropoietin stimulate agent ( ESAs ) prospective manner , treatment anemia end stage renal disease ( ESRD ) patient . * Patients Methods : All haemodialysis patient Qatar treat short act Epoetin alfa beta screen . Eligible patient randomize , either continue previous regimen Epoetin , receive Darbepoetin alfa continuous erythropoietin receptor activator ( C.E.R.A ) total period 40 week . All group assess end study safety efficacy parameter .</brief_summary>
	<brief_title>Comparison Among Erythropoietin Stimulating Agents</brief_title>
	<detailed_description>- Objectives study 1 . Primary Objective To evaluate efficacy continuous erythropoietin receptor activator ( C.E.R.A . ) Darbepoetin Alfa , maintain Hemoglobin level - within target recommend range - among ESRD patient , direct comparison currently available ESA ( Epoetin alfa beta ) . 2 . Secondary Objective To compare safety profile three group ( Epoetin , Darbepoetin alpha , C.E.R.A . ) prevalence associate morbidity mortality . - Patients Methods 1 . Study Subjects All haemodialysis patient main dialysis center Qatar ( Doha , Alkhour Alwakra ) screen . 2 . Study Design This prospective , randomize , comparative , open label study . The study pass three phase ; first phase screen period 4 week , 2nd phase titration period 12 week third phase evaluation period 24 week . All patient enter 4-week screening/baseline period continue receive previous Epoetin beta alfa treatment . Eligible patient randomly assign ( 1:1:1 ) , either continue previous dose route administration Epoetin alpha beta ( Epoetin group ) , receive Darbepoetin alfa ( Aranesp ® Amgen ) every week 2weeks ( Darbepoetin group ) methoxy polyethylene glycol-epoetin beta ( Mircera ® Roche , F. Hoffmann-La Roche , Basel , Switzerland ) monthly ( C.E.R.A . group ) . In second group Subjects receive Epoetin alpha/ beta two three time week switch Darbepoetin alfa week , receive Epoetin alpha beta week switch Darbepoetin alfa every 2 week . Two hundred IU Epoetin : 1 mcg Darbepoetin alfa ratio use determine start dose Darbepoetin alfa . If dose Epoetin alpha beta equate exactly unit dose Darbepoetin alfa switching , nearest available unit dose Darbepoetin alfa use . Darbepoetin alfa dos adjust accord approve prescribing information , without additional restriction . In third group Mircera® ( F.Hoffmann-La Roche Ltd. , Basel , Switzerland ) provide pre-filled syrinx . Intravenous monthly administration carry . The initial dose 120 mcg , 200 mcg 360 mcg , provide patient previously receive weekly dose Epoetin alpha/ beta less 8000 IU , 8000 to16 000 IU than16000IU respectively . Doses C.E.R.A . adjust accord protocol monthly . Doses C.E.R.A . decrease 25 % Hb value &gt; 12 ≤13 g/dL increase 25 % Hb &lt; 11 ≥10 g/dL . C.E.R.A . dose increase 50 % Hb &lt; 10 g/dL . Treatment interrupt temporarily Hb exceed 13 g/dL . The dos patient adjust haemoglobin concentration would remain within target range 11-12 g/dL study . Iron supplementation initiate intensified accord centre practice case iron deficiency ( serum ferritin &lt; 100 μg/L , transferrin saturation &lt; 20 % , hypochromic red blood cell &gt; 10 % ) discontinue patient serum ferritin level &gt; 800 μg/L transfer saturation &gt; 50 % . The study conduct accordance revise Declaration Helsinki , study protocol approve internal research committee . Written inform consent obtain studied patient . 3 . Sample Size Technique One hundred ten patient plan recruit arm accord number eligible subject screen period . ( Alpha= 0.05 , B= 0.20 66 % response rate MIRCERA , 40.4 % response rate darbepoetin alpha So compare sample size happen 107 individual group . [ Statistical method rate proportion Joseph L. Fleiss ( 2nd . 1981 , John Wiley &amp; Sons , NY ) , chapter 3 ] . The study primarily evaluate whole population haemodialysis patient Qatar . Laboratory assessment haemoglobin , haematocrit , white blood cell count , platelet count measure weekly interval . Aspartate amino transferase , alanine aminotransferase , albumin , alkaline phosphatase , C- reactive protein , potassium , phosphorus , serum ferritin , serum iron , serum transferrin , total iron-binding capacity measure monthly interval . Physical examination include chest , heart , abdomen examination evaluation volume status perform baseline , monthly final visit . Fractional clearance urea ( Kt/V ) urea reduction ratio use assess adequacy haemodialysis baseline monthly unit protocol . Data collect data collection form . 4 . Data Management Analysis plan Collected data fed excel sheet convert SPSS 14.0 statistical package analysis . Descriptive statistic perform continuous categorical variable appropriately . Parametric non parametric statistical technique apply see significance difference group . P value 0.05 ( two tail ) less consider statistical significant level .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Aged ≥18 year stable chronic renal anemia ( hemoglobin range 1012 g/dL ) regular haemodialysis 3 x week urea reduction ratio great equal 65 % KT/V ( K dialyzer clearance urea , dialysis time , V volume distribution urea , approximately equal patient 's total body water ) great equal 1.2 . Patients must receive haemodialysis three time weekly ≥12 week screen 4week screening/baseline period . Eligible patient must stable hemoglobin concentration ( stable define ≤25 % change weekly dose ESA 8 week ) . Recruited patient must undergone continuous maintenance intravenous conventional Epoetin alpha beta therapy ≥8 week screen screening/baseline . Patients adequate iron status , define serum ferritin ≥100 μg/L transferrin saturation ≥20 % . New York Heart Association ( NYHA ) class III IV congestive heart failure Uncontrolled hypertension ( define predialysis diastolic blood pressure 105 mmHg systolic BP≥ 160 mmHg screen period ) Evidence uncontrolled hyperparathyroidism ( define parathyroid hormone level &gt; 1000 pg/ml response conventional treatment hyperparathyroidism accord Kidney Disease Outcomes Quality Initiative ( KDOQI ) guide line 12 month prior baseline ) Treatment grand mal epilepsy Haematological , inflammatory infectious condition might interfere erythropoietin response Received red blood cell transfusion within 12 week screen screening/baseline period . reactive protein &gt; 30 mg/L The likelihood early withdrawal ; life expectancy &lt; 12 month Poor compliance dialysis treatment , evidence &gt; 2 missed treatment monthly previous 3 months10 . Refuse involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Erythropoetin Stimulating Agents</keyword>
	<keyword>Comparison</keyword>
</DOC>